Biomed Central Ltd

SHERPA: Unknown

People

  1. Shah
    Shah
  2. Chawla
    Chawla
  3. Lin
    Lin
  4. Motzer
    Motzer
  5. Postow
    Postow
  6. Schoenfeld
    Schoenfeld
  7. Voss
    Voss

Groups

  1. Department of Medicine (7)
  2. Genitourinary Oncology Service (7)
  3. Solid Tumor Oncology Division (7)
  4. Biostatistics Service (1)
  5. Division of Subspecialty Medicine (1)
  6. Epidemiology and Biostatistics (1)
  7. Hematologic Malignancies, Division of (1)
  8. Hematology-Oncology Fellows (1)
  9. Melanoma Disease Management Team (1)
  10. Melanoma and Immunotherapeutics Service (1)
Search Within
  1. "Neil Shah"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (3)
Groups
  1. Department of Medicine (7)
  2. Genitourinary Oncology Service (7)
  3. Solid Tumor Oncology Division (7)
  4. Biostatistics Service (1)
  5. Division of Subspecialty Medicine (1)
  6. Epidemiology and Biostatistics (1)

More Groups

People
  1. Neil Shah (7)
  2. Adam Schoenfeld (1)
  3. Allison Betof Warner (1)
  4. Hira Rizvi (1)
  5. I-Hsin Lin (1)
  6. Jason Beattie (1)

More People

Years
  1. 2022 (3)
  2. 2021 (3)
  3. 2019 (1)
Publications
  1. Journal for ImmunoTherapy of Cancer (7)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prediction of best response for NSCLC patients receiving immunotherapy by machine learning models
    Meeting Abstract

    Zhang, Y.; Gupta, S.; Belouali, A.; Lev-Ari, S.; Shah, N.; Krishnamurthy, K.; Serzan, M.; Alaoui, A.; McGarvey, P.; Atkins, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • A multicohort phase 1b study (STELLAR-002) of XL092 in combination with immunotherapy in patients with advanced solid tumors
    Meeting Abstract

    McGregor, B.; Choueiri, T.; Shah, N.; Bajaj, A.; Chahoud, J.; O'Neil, B.; Michalski, J.; Garmezy, B.; Jin, L.; Aziz, U.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): A matched cohort study from the International Catch-It Consortium
    Meeting Abstract

    El Zarif, T.; Nassar, A.; Adib, E.; Fitzgerald, B.; Huang, J.; Mouhieddine, T.; Nonato, T.; McKay, R.; Li, M.; Mittra, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • A phase 1b/2 randomized study of Avb-S6-500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment
    Meeting Abstract

    Beckermann, K.; Vogelzang, N.; Shifeng, M.; Ornstein, M.; Shah, N.; Hammers, H.; Campbell, M.; Gao, X.; McDermott, D.; Anderson, R.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma
    Journal Article

    Gibney, G. T.; Zaemes, J.; Shand, S.; Shah, N. J.; Swoboda, D.; Gardner, K.; Radfar, A.; Petronic-Rosic, V.; Reilly, M. J.; Al-Refaie, W. B.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
    Journal Article

    Beattie, J.; Rizvi, H.; Fuentes, P.; Luo, J.; Schoenfeld, A.; Lin, I. H.; Postow, M.; Callahan, M.; Voss, M. H.; Shah, N. J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
    Journal Article

    Shah, N. J.; Al-Shbool, G.; Blackburn, M.; Cook, M.; Belouali, A.; Liu, S. V.; Madhavan, S.; He, A. R.; Atkins, M. B.; Gibney, G. T.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save